Details

Autor(en) / Beteiligte

• Kim, Jinkuk
• Lee, In-Hee
• Cho, Hee Jin
• Park, Chul-Kee
• Jung, Yang-Soon
• Kim, Yanghee
• Nam, So Hee
• Kim, Byung Sup
• Johnson, Mark D.
• Kong, Doo-Sik
• Seol, Ho Jun
• Lee, Jung-Il
• Joo, Kyeung Min
• Yoon, Yeup
• Park, Woong-Yang
• Lee, Jeongwu
• Park, Peter J.
• Nam, Do-Hyun

Titel

Spatiotemporal Evolution of the Primary Glioblastoma Genome

Ist Teil von

• Cancer cell, 2015-09, Vol.28 (3), p.318-328

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2015

Quelle

MEDLINE

Beschreibungen/Notizen

• Tumor recurrence following treatment is the major cause of mortality for glioblastoma multiforme (GBM) patients. Thus, insights on the evolutionary process at recurrence are critical for improved patient care. Here, we describe our genomic analyses of the initial and recurrent tumor specimens from each of 38 GBM patients. A substantial divergence in the landscape of driver alterations was associated with distant appearance of a recurrent tumor from the initial tumor, suggesting that the genomic profile of the initial tumor can mislead targeted therapies for the distally recurred tumor. In addition, in contrast to IDH1-mutated gliomas, IDH1-wild-type primary GBMs rarely developed hypermutation following temozolomide (TMZ) treatment, indicating low risk for TMZ-induced hypermutation for these tumors under the standard regimen. [Display omitted] •Distant recurrence predicts branched evolution of the paired tumors•Distant recurrence frequently involves divergence in key GBM driver alterations•Recurrent GBMs have more aberrations in core GBM driver pathways than initial GBMs•TMZ-induced hypermutation is rare in IDH1-wild-type primary GBMs Kim et al. find that glioblastomas recurring at distant sites have driver genetic alterations very different from those of matched initial tumors. They also show that, in contrast to IDH1-mutated tumors, IDH1-wild-type primary glioblastomas rarely develop hypermutation following temozolomide treatment.